Videos

Live from Asembia AXS26, Kim Plesnarski shares what a best-in-class reimbursement and support model looks like.

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years.

Live from Asembia AXS26, Austin Russian examines how specialty therapy launches are evolving.

Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

Miranda Delatore and Megan Wetzel share their outlook on the future of specialty pharmacy.

Jessica Lovett discusses specialty pharma commercialization timelines, and how the Canadian market is different from the US.

Tommy Bramley explains how real-world evidence can be leveraged to benefit patient outcomes in specialty pharma.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Kieran Daly explains how adherence and proof of use strategies improve commercial outcomes and the patient experience in specialty pharma.

Kim Plesnarski explains what the biggest inefficiencies are in specialty pharma partnerships.

Joel Wayment discusses how the cold chain can be more sustainable.

Jennifer Lospinoso explains how cell and gene therapies are reshaping specialty pharmacy commercialization.

CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains.

Ahead of LogiPharma Europe 2026, Richard Harrop explains why packaging must be more patient-centric.

Anthony “TJ” Rizzo shares his outlook on the future of pharma cold chain technology.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.

Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.

Anthony “TJ” Rizzo explains what makes an effective supply chain partnership, and how tech can be deployed alongside human experience.

Richard Harrop shares how pharma can strike a balance between performance, sustainability, and resilience in packaging design.

Ahead of his presentation at LogiPharma 2026, Anthony “TJ” Rizzo discusses how automation and real-time monitoring can be deployed in supply chains.

Jessica Ledesma explores how hospital pharmacies are adopting autonomous cold storage to protect high-value medications.

Laura Blair explains why streamlining the patient journey via and simpler tools help ensure adherence from the point of prescription.

Laura Blair discusses what makes enrollment friction, and how the right balance of AI and human support can improve hub utilization and speed to therapy.

Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.